Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 8/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 3/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326792 | 0.78 | ITGB3 (0.45) | MIFGRM2GRM5GRM1CA2 | |
| SCHEMBL20459128 | 0.65 | GFER (0.45) | ESR1ESR2ALDH1A1 | |
| Hydroquinone SCHEMBL8616475 | 0.64 | FFAR3 (0.59) | NR3C1CA2CAMK2AESR1ESR2 | |
| Hydroquinone SCHEMBL9067666 | 0.64 | FFAR3 (0.59) | NR3C1CA2CAMK2AESR1ESR2 | |
| SCHEMBL23357092 | 0.64 | MAOB (0.41) | HSD11B1SLC6A2SLC6A4 | |
| Hydroquinone SCHEMBL10904652 | 0.62 | CA2 (0.52) | NR3C1CA2CAMK2AESR1ESR2 | |
| SCHEMBL10670175 | 0.61 | ESR2 (0.41) | ESR1ESR2SLC6A4CYP3A4 | |
| SCHEMBL6325366 | 0.61 | ITGB3 (0.50) | MIFCA2HSD11B1ALDH1A1 | |
| SCHEMBL21065268 | 0.61 | ESR2 (0.41) | ESR1ESR2ALDH1A1CYP3A4 | |
| SCHEMBL16084399 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005051904-A2 | NOVEL PROCESSES FOR THE SYNTHESIS OF CYCLOPROPYL COMPOUNDS | PHARMACIA CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | MIF 1429/4885NR3C1 945/4885GRM2 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.